1- Roberson, E.D., Bowcock, A. M. (2010). Psoriasis genetics: breaking the barrier. Trends in Genetics, 26(9), 415-423.
2- Nickoloff, B. J., & Nestle, F. O. (2004). Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. The Journal of clinical investigation, 113(12), 1664-1675.
3- Lui, H. and Mamelak, A.J. (2009): Psoraisis. Emedicine. Medscape.com.
4- Finlay, A.Y. (2005). Current severe psoriasis and the rule of tens. British Journal of Dermatology, 152(5), 861-867.
5- Mehta, N. N., Li, K., Szapary, P., Krueger, J., & Brodmerkel, C. (2013). Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis. Journal of translational medicine, 11(1), 1-8.
6- Du Clos, T. W., & Mold, C. (2004). C-reactive protein. Immunologic research, 30(3), 261-277.
7- Lago, F., Dieguez, C., Gómez-Reino, J., & Gualillo, O. (2007). Adipokines as emerging mediators of immune response and inflammation. Nature clinical practice Rheumatology, 3(12), 716-724.
8- Heiker, J. T. (2014). Vaspin (serpinA12) in obesity, insulin resistance, and inflammation. Journal of Peptide Science, 20(5), 299-306.
9- Youn, B. S., Klöting, N., Kratzsch, J., Lee, N., Park, J. W., Song, E. S., ... & Blüher, M. (2008). Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes, 57(2), 372-377.
10- Gökalp, H. (2018). Effect of psoriasis severity on inflammation parameters: controlled study. Turk J Dermatol, 52.
11- Serwin, A.B., Wasowicz, W., & Chodynicka, B. (2006). Selenium supplementation, soluble tumor necrosis factor-α receptor type 1, and C-reactive protein during psoriasis therapy with narrowband ultraviolet B. Nutrition, 22(9), 860-864.
12- Uysal, S., Yilmaz, F. M., Karatoprak, K., Artuz, F., & Cumbul, N. U. (2014). The levels of serum pentraxin3, CRP, fetuin-A, and insulin in patients with psoriasis. Eur Rev Med Pharmacol Sci, 18(22), 3453-8.
13- Jain, V. K., & Lal, H. (2011). C-reactive protein and uric acid levels in patients with psoriasis. Indian journal of clinical biochemistry, 26(3), 309-311.
14- Biljan, D., Šitum, M., Kostović, K., Batinac, T., & Matišić, D. (2009). Acute phase proteins in psoriasis. Collegium antropologicum, 33(1), 83-86.
15- Coimbra, S., Oliveira, H., Reis, F., Belo, L., Rocha, S., Quintanilha, A& Santos‐Silva, A. (2010). C‐reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. Journal of the European Academy of Dermatology and Venereology, 24(7), 789-796.
16- Chodorowska, G., Wojnowska, D., & Juszkiewicz‐Borowiec, M. (2004). C‐reactive protein and α2‐macroglobulin plasma activity in medium–severe and severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 18(2), 180-183.
17- Strober, B., Teller, C., Yamauchi, P., Miller, J. L., Hooper, M., Yang, Y. C., & Dann, F. (2008). Effects of etanercept on C‐reactive protein levels in psoriasis and psoriatic arthritis. British Journal of Dermatology, 159(2), 322-330.
18- Kanelleas, A., Liapi, C., Katoulis, A., Stavropoulos, P., Avgerinou, G., Georgala, S & Katsambas, A. (2011). The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clinical and Experimental Dermatology: Clinical dermatology, 36(8), 845-850.
19- Saalbach, A., Tremel, J., Herbert, D., Schwede, K., Wandel, E., Schirmer, C., ... & Simon, J. C. (2016). Anti-inflammatory action of keratinocyte-derived vaspin: relevance for the pathogenesis of psoriasis. The American journal of pathology, 186(3), 639-651.
20- Ataseven, A., & Kesli, R. (2014). Novel inflammatory markers in psoriasis vulgaris: vaspin, vascular adhesion protein-1 (VAP-1), and YKL-40. Giornale italiano di dermatologia e venereologia: organo ufficiale, Societa italiana di dermatologia e sifilografia, 151(3), 244-250.